Market Cap: $1.65B
UI
Ultragenyx Pharmaceutical Inc.
RARE
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.65B
Ultragenyx Pharmaceutical (Ticker: RARE) showcases its commitment to innovative therapies for rare genetic disorders, demonstrated recently during CEO Emil Kakkis's engagement at Goldman Sachs' 47th A…
Ultragenyx Pharmaceutical (Ticker: RARE) faces increased scrutiny as a law firm launches an investigation into its potential misrepresentation of product data. Kuehn Law Investigates Ultragenyx for Po…
Legal Challenges Loom for Ultragenyx as Investors File Class Action Lawsuit Ultragenyx Pharmaceutical Inc. faces significant legal challenges following the announcement of disappointing results from i…
Ultragenyx Faces Class Action Over Allegations of Misleading Statements Regarding Setrusumab A class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc. by Levi & Korsinsky, LLP,…
Ultragenyx Faces Class Action Lawsuits Over Alleged Misstatements in Drug Trials Ultragenyx Pharmaceutical Inc. is currently embroiled in legal challenges as Levi & Korsinsky and Robbins Geller Rudman…
Legal Challenges Loom for Ultragenyx as Class Action Lawsuit Emerges In a significant development that underscores the legal pressures faced by Ultragenyx Pharmaceutical Inc., a class action securitie…
Ultragenyx Faces Class Action Lawsuit Over Misleading Statements Regarding Setrusumab Trials Ultragenyx Pharmaceutical Inc. is currently embroiled in a class action lawsuit initiated by Robbins Geller…
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Drug Efficacy Misrepresentation Ultragenyx Pharmaceutical Inc. is currently embroiled in a class action lawsuit filed by the Schall Law Firm,…
Ultragenyx Pharmaceutical Faces Legal Scrutiny Over Drug Misrepresentation Allegations Ultragenyx Pharmaceutical Inc. is currently embroiled in legal challenges following allegations of misleading com…
### Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Drug Misrepresentation Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in rare diseases, finds itself at the cent…
Ultragenyx Pharmaceutical Under Legal Scrutiny Amid Class Action Lawsuit Claims Ultragenyx Pharmaceutical Inc. finds itself at the center of a class action lawsuit, filed in connection with its Phase…
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Misrepresentation in Clinical Trials In a significant development for Ultragenyx Pharmaceutical Inc., the Rosen Law Firm announces a class act…
Ultragenyx Faces Legal Challenges Over Drug Efficacy Allegations Ultragenyx Pharmaceutical Inc. is currently embroiled in significant legal challenges following a class action lawsuit related to alleg…
Ultragenyx Faces Class Action Lawsuit Over Misleading Efficacy Claims on Setrusumab Ultragenyx Pharmaceutical Inc. currently confronts significant legal challenges as a class action lawsuit has been f…
Ultragenyx Faces Class Action Lawsuits Over Alleged Misleading Statements on Drug Candidate Ultragenyx Pharmaceutical Inc. is currently embroiled in legal challenges following the announcement of clas…
### Ultragenyx Pharmaceutical Faces Class Action Lawsuits Over Phase 3 Trial Failures Ultragenyx Pharmaceutical Inc. is embroiled in multiple class action lawsuits following the announcement of disapp…
Legal Turmoil Surrounds Ultragenyx Pharmaceutical Over Misleading Drug Efficacy Claims Ultragenyx Pharmaceutical Inc. faces escalating legal challenges as allegations mount regarding the handling of d…
Ultragenyx Faces Class Action Over Setrusumab Trials The development of Ultragenyx Pharmaceutical Inc.'s treatment setrusumab (UX 143) for Osteogenesis Imperfecta (OI) has come under scrutiny as a cla…
Ultragenyx Faces Legal Challenges Over Setrusumab Efficacy Claims Ultragenyx Pharmaceutical Inc. confronts a class action lawsuit that raises serious concerns about its representations regarding setru…
Ultragenyx Faces Legal Scrutiny Over Misleading Statements Regarding Setrusumab Effectiveness Ultragenyx Pharmaceutical Inc. is currently embroiled in allegations of securities fraud connected to its…
Ultragenyx Pharmaceutical Faces Class Action Suit Over Misleading Drug Trial Claims Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is currently embroiled in a class action lawsuit filed by the Schall L…
Ultragenyx faces scrutiny after Phase III ORBIT misses fracture endpoint ORBIT trial outcome and company statements come under legal challenge Ultragenyx Pharmaceutical is facing litigation after its…
Housing trend highlights patient-centered care for rare disease biotech Ultragenyx Pharmaceutical and other rare-disease biotechs are spotlighting personalization and community support as central comp…
Ultragenyx faces class action over setrusumab trial disclosures Allegations focus on Phase III Orbit trial statements A securities fraud class action is underway against Ultragenyx Pharmaceutical, wit…
Allegations Focus on Setrusumab Trial Disclosures Plaintiffs allege Ultragenyx Pharmaceutical misleads investors about the clinical prospects of setrusumab, its antibody candidate for osteogenesis imp…